PL2992015T3 - Leczenie skojarzone niefukozylowanym przeciwciałem anty-CD20 z koniugatem przeciwciało anty-CD22-lek - Google Patents
Leczenie skojarzone niefukozylowanym przeciwciałem anty-CD20 z koniugatem przeciwciało anty-CD22-lekInfo
- Publication number
- PL2992015T3 PL2992015T3 PL14721825T PL14721825T PL2992015T3 PL 2992015 T3 PL2992015 T3 PL 2992015T3 PL 14721825 T PL14721825 T PL 14721825T PL 14721825 T PL14721825 T PL 14721825T PL 2992015 T3 PL2992015 T3 PL 2992015T3
- Authority
- PL
- Poland
- Prior art keywords
- antibody
- afucosylated
- combination therapy
- drug conjugate
- conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818810P | 2013-05-02 | 2013-05-02 | |
| PCT/EP2014/058831 WO2014177617A1 (en) | 2013-05-02 | 2014-04-30 | Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate |
| EP14721825.9A EP2992015B1 (en) | 2013-05-02 | 2014-04-30 | Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2992015T3 true PL2992015T3 (pl) | 2019-01-31 |
Family
ID=50678173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14721825T PL2992015T3 (pl) | 2013-05-02 | 2014-04-30 | Leczenie skojarzone niefukozylowanym przeciwciałem anty-CD20 z koniugatem przeciwciało anty-CD22-lek |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20150010540A1 (pl) |
| EP (1) | EP2992015B1 (pl) |
| JP (1) | JP6207721B2 (pl) |
| KR (1) | KR101817409B1 (pl) |
| CN (1) | CN105143268A (pl) |
| AR (1) | AR096184A1 (pl) |
| AU (1) | AU2014261456B2 (pl) |
| BR (1) | BR112015027474A8 (pl) |
| CA (1) | CA2904040A1 (pl) |
| ES (1) | ES2693370T3 (pl) |
| HK (1) | HK1211962A1 (pl) |
| IL (1) | IL242161B (pl) |
| MX (1) | MX370829B (pl) |
| MY (1) | MY192404A (pl) |
| NZ (1) | NZ711867A (pl) |
| PL (1) | PL2992015T3 (pl) |
| RU (1) | RU2700092C2 (pl) |
| SG (1) | SG11201509026VA (pl) |
| WO (1) | WO2014177617A1 (pl) |
| ZA (1) | ZA201506512B (pl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3082876B1 (en) | 2013-12-16 | 2018-01-17 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| CN107592812A (zh) * | 2015-05-11 | 2018-01-16 | 豪夫迈·罗氏有限公司 | 治疗狼疮性肾炎的组合物和方法 |
| AU2016368469B2 (en) * | 2015-12-09 | 2023-11-02 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody for reducing formation of anti-drug antibodies |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3600416B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| US20200405879A1 (en) * | 2017-04-20 | 2020-12-31 | Adc Therapeutics Sa | Combination therapy |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| EP4433506A1 (en) | 2021-11-16 | 2024-09-25 | Genentech, Inc. | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6836301A (en) * | 2000-06-20 | 2002-01-02 | Idec Pharma Corp | Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
| SG187991A1 (en) * | 2002-05-02 | 2013-03-28 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| US8420086B2 (en) * | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| PT1692182E (pt) * | 2003-11-05 | 2010-05-13 | Roche Glycart Ag | Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida |
| RU2448117C2 (ru) * | 2003-11-06 | 2012-04-20 | Сиэтл Дженетикс, Инк. | Монометилвалиновые соединения, способные образовывать конъюгаты с лигандами |
| WO2007140371A2 (en) * | 2006-05-30 | 2007-12-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| RU2487877C2 (ru) * | 2008-04-30 | 2013-07-20 | Иммьюноджен, Инк. | Высокоэффективные конъюгаты и гидрофильные сшивающие агенты (линкеры) |
| RU2012109451A (ru) * | 2009-08-14 | 2013-09-27 | Роше Гликарт Аг | Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном |
| MX342590B (es) * | 2010-04-27 | 2016-10-05 | Roche Glycart Ag | Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor. |
| CN103037903A (zh) * | 2010-05-18 | 2013-04-10 | 天蓝制药公司 | 用于治疗自身免疫性疾病或其它疾病的组合物和方法 |
| AR082693A1 (es) * | 2010-08-17 | 2012-12-26 | Roche Glycart Ag | Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf |
| CA2827170A1 (en) * | 2011-02-11 | 2012-08-16 | David M. Hilbert | Monovalent and multivalent multispecific complexes and uses thereof |
-
2014
- 2014-04-30 JP JP2016511055A patent/JP6207721B2/ja not_active Expired - Fee Related
- 2014-04-30 AU AU2014261456A patent/AU2014261456B2/en not_active Ceased
- 2014-04-30 MY MYPI2015703897A patent/MY192404A/en unknown
- 2014-04-30 MX MX2015014501A patent/MX370829B/es active IP Right Grant
- 2014-04-30 SG SG11201509026VA patent/SG11201509026VA/en unknown
- 2014-04-30 ES ES14721825.9T patent/ES2693370T3/es active Active
- 2014-04-30 HK HK15112884.7A patent/HK1211962A1/xx unknown
- 2014-04-30 RU RU2015151455A patent/RU2700092C2/ru active
- 2014-04-30 US US14/265,857 patent/US20150010540A1/en not_active Abandoned
- 2014-04-30 AR ARP140101795A patent/AR096184A1/es unknown
- 2014-04-30 NZ NZ711867A patent/NZ711867A/en not_active IP Right Cessation
- 2014-04-30 EP EP14721825.9A patent/EP2992015B1/en active Active
- 2014-04-30 CN CN201480023315.6A patent/CN105143268A/zh active Pending
- 2014-04-30 BR BR112015027474A patent/BR112015027474A8/pt not_active Application Discontinuation
- 2014-04-30 PL PL14721825T patent/PL2992015T3/pl unknown
- 2014-04-30 WO PCT/EP2014/058831 patent/WO2014177617A1/en not_active Ceased
- 2014-04-30 CA CA2904040A patent/CA2904040A1/en not_active Abandoned
- 2014-04-30 KR KR1020157031017A patent/KR101817409B1/ko not_active Expired - Fee Related
-
2015
- 2015-09-04 ZA ZA2015/06512A patent/ZA201506512B/en unknown
- 2015-10-19 IL IL242161A patent/IL242161B/en active IP Right Grant
-
2017
- 2017-03-07 US US15/452,577 patent/US20170306040A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016519125A (ja) | 2016-06-30 |
| AR096184A1 (es) | 2015-12-16 |
| CA2904040A1 (en) | 2014-11-06 |
| KR20150139883A (ko) | 2015-12-14 |
| MY192404A (en) | 2022-08-19 |
| EP2992015B1 (en) | 2018-08-29 |
| BR112015027474A2 (pt) | 2017-12-05 |
| AU2014261456A1 (en) | 2015-09-24 |
| RU2700092C2 (ru) | 2019-09-12 |
| ES2693370T3 (es) | 2018-12-11 |
| IL242161B (en) | 2019-08-29 |
| BR112015027474A8 (pt) | 2018-01-23 |
| US20150010540A1 (en) | 2015-01-08 |
| AU2014261456B2 (en) | 2018-10-04 |
| EP2992015A1 (en) | 2016-03-09 |
| SG11201509026VA (en) | 2015-12-30 |
| US20170306040A1 (en) | 2017-10-26 |
| JP6207721B2 (ja) | 2017-10-04 |
| MX370829B (es) | 2020-01-08 |
| HK1211962A1 (en) | 2016-06-03 |
| ZA201506512B (en) | 2017-03-26 |
| KR101817409B1 (ko) | 2018-01-10 |
| WO2014177617A1 (en) | 2014-11-06 |
| RU2015151455A (ru) | 2017-06-07 |
| NZ711867A (en) | 2020-07-31 |
| MX2015014501A (es) | 2016-02-09 |
| CN105143268A (zh) | 2015-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2500038I1 (hu) | Anti-trop2 antitest-gyógyszer konjugátum | |
| IL242161B (en) | Combined treatment of the fucosylated 20cd antibody with the 22cd antibody conjugated to the drug | |
| SG11201509009WA (en) | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A CD79b ANTIBODY-DRUG CONJUGATE | |
| ZA201505656B (en) | Antibody drug conjugates | |
| IL246277A0 (en) | Peptide-mimicking compounds and their antibody-drug conjugates | |
| ZA201603697B (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| IL238567A0 (en) | Antibodies against notch3 and antibody-drug conjugates | |
| ZA201602501B (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| IL243900B (en) | Antibodies to cxcr4 and their conjugates with drugs | |
| IL241532B (en) | Pyrrolobenzodiazepines and their conjugates | |
| ZA201506668B (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| ZA201505753B (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| ZA201508487B (en) | Antibody drug conjugates | |
| GB201317981D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| PT2968552T (pt) | Anticorpo dos agentes alvo, combinações e uso para os mesmos | |
| SG11201506086SA (en) | Site-specific antibody-drug conjugation through glycoengineering | |
| IL245437A0 (en) | Antibodies against efna4 and antibody-drug pairs | |
| HUE037909T2 (hu) | Immuno-képalkotó ágens antitest-farmakon-konjugátum terápiával történõ alkalmazásra | |
| HUE037456T2 (hu) | Immuno-képalkotó ágens ellenanyag-drog-konjugátum terápiával történõ alkalmazásra | |
| GB201310472D0 (en) | Antibody-drug conjugates | |
| IL240371A0 (en) | Immunogenic imaging agent for use with drug-antibody conjugate therapy | |
| IL240370A0 (en) | Immunogenic imaging agent for use with drug-antibody conjugate therapy |